{
  "ptid_time": "035_S_4414_2012-03-19",
  "img_path": "/data/qiuhui/data/adni/images/035_S_4414/2012-03-19/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 17,130 mm³, 23.3% below the reference mean. With a Z-score of -0.58 (28.0th percentile), this represents normal volume ; hippocampal volume measures 6,788 mm³, 11.7% below the reference mean. With a Z-score of -1.31 (9.5th percentile), this represents mild atrophy; whole brain volume measures 1,001,120 mm³, 2.7% below the reference mean. With a Z-score of -0.34 (36.7th percentile), this represents normal volume ; entorhinal cortex volume measures 3,032 mm³, 22.1% below the reference mean. With a Z-score of -1.71 (4.3th percentile), this represents moderate atrophy; fusiform gyrus volume measures 15,592 mm³, 14.4% below the reference mean. With a Z-score of -1.62 (5.3th percentile), this represents moderate atrophy; middle temporal gyrus volume measures 18,960 mm³, 7.6% below the reference mean. With a Z-score of -0.68 (25.0th percentile), this represents normal volume . ",
  "text_data": "Age is 60.8 years. Gender is Female. Education: 18 years. Handedness: Right. Race: White. Medical history: Psychiatric; Endocrine-Metabolic. MMSE: 28.0. MoCA: 20.0. Logical Memory: 3.0. APOEε4 alleles: 1.0. Biomarker levels: Florbetapir (AV45): 1.22 SUVR (mild elevated); Amyloid beta: 969.70 pg/mL (normal ); Total tau: 402.60 pg/mL (significant elevated); Phosphorylated tau: 43.22 pg/mL (significant elevated). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging shows mild hippocampal atrophy and moderate atrophy in the entorhinal cortex and fusiform gyrus—key regions affected in Alzheimer’s disease (AD). The clinical data supports this with a normal Aβ but elevated T-tau and P-tau (suggestive of AD pathology), along with a low MoCA (20/30) despite a near-normal MMSE (28/30), indicating possible early cognitive impairment.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely due to Alzheimer’s pathology given biomarker profile).  \n**Confidence:** **High** (due to concordance between structural atrophy in AD-vulnerable regions, tau elevation, and cognitive decline on MoCA).  \n\n*Note:* The absence of Aβ positivity makes this atypical for AD, but elevated tau with neurodegeneration in AD-related regions strongly suggests an AD-like process (e.g., primary age-related tauopathy [PART] or atypical AD). A follow-up FDG-PET or clinical progression monitoring would help clarify.",
  "timestamp": "2025-07-26T05:56:05.180015"
}